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What is the key question? 
How can we best optimise the risk / benefit balance of mTOR inhibition for loss of lung function in 
individuals with LAM? 
What is the bottom line? 
Loss of lung function may continue in some individuals treated with rapamycin and a poor response to the 
drug is more likely in those with lower lung function and longer disease duration at the start of treatment. 
Lower levels of rapamycin are associated with fewer side effects but equal benefit compared with higher 
levels. 
Why read on? 
We have used a prospective national cohort study to understand the relationship between rapamycin 
levels, lung function response and side effects to improve the use of mTOR inhibitors in women with LAM.  
Abstract 
Rationale mTOR inhibitors reduce loss of lung function in LAM although their benefit varies between 
individuals. We examined lung function response and side effects to rapamycin in a national cohort. 
Methods Subjects were receiving rapamycin for progressive lung disease. Clinical evaluation, detailed 
phenotyping, serial lung function, rapamycin and safety monitoring were performed according to a clinical 
protocol. Lung function change, measured as FEV1 slope (ΔFEV1), was reported for those treated for one year 
or longer. 
Results Rapamycin was associated with improved ΔFEV1 in 21 individuals where pre-treatment data were 
available (p<0.0001). In 47 treated for a mean duration 35.8 months, mean ΔFEV1 was +11 (SD 75) ml/yr 
although varied from +254 to -148 ml/yr. The quartile with the highest positive ΔFEV1 had greater pre-
treatment FEV1 (p=0.02) and shorter disease durations (p=0.02) than the lowest quartile. Serum rapamycin 
level was positively associated with side effects (p=0.02) but not ΔFEV1 over one year. Within the first 
month of therapy, apthous ulcers, nausea and diarrhoea were associated with higher rapamycin levels. 
Acne, oedema and menstrual irregularities tended to increase over the first year of therapy. At the end of 
observation the prevalence of side effects was 5% or less. 
Conclusions Rapamycin reduces lung function loss in LAM, although in some ΔFEV1 continues to fall at an 
accelerated rate. Poor response to rapamycin was associated with lower pre-treatment lung function and 
longer disease duration but not serum level. Early intervention with low dose rapamycin may preserve lung 
function and reduce side effects.   
 
Introduction. 
Lymphangioleiomyomatosis (LAM) is a multisystem disease characterised by lung cysts, lymphatic 
abnormalities and a high prevalence of kidney angiomyolipomas1. As a sporadic disease LAM affects almost 
exclusively women with an incidence of 0.3 per million women per year: however LAM is common in the 
autosomal genetic disease tuberous sclerosis complex (TSC-LAM) where it affects around half of adult 
women and some men2. In LAM, cysts replace the lung parenchyma resulting in recurrent pneumothorax 
and dyspnoea which can progress over a variable period of years to result in respiratory failure. Lymphatic 
involvement can cause lymphatic masses and chylous collections in the thorax and abdomen. 
Angiomyolipomas are frequently small and asymptomatic but may enlarge and bleed necessitating urgent 
treatment.  
The lungs and lymphatics of women with LAM are infiltrated by LAM cells; a clone of cells expressing 
markers of both melanogenesis and smooth muscle differentiation. LAM cells in both sporadic and TSC-
LAM have bi-allelic inactivating mutations in either the TSC-1, or more frequently the TSC-2 gene3. Loss of 
function of TSC-1/2 leads to constitutive activation of the mechanistic target of rapamycin (mTOR) resulting 
in altered translation of 5 prime cap dependent genes, uncontrolled proliferation, dependence on 
autophagy and a metabolic shift toward energy generation by glycolysis4. Suppression of mTOR signalling in 
women with LAM is associated with reduced loss of lung function5-7, reduction in angiomyolipoma volume8-
10 and reduced chylous complications11. The use of mTOR inhibitors has become the standard of care for 
progressive lung disease in sporadic LAM12 and in TSC for LAM, angiomyolipoma and sub-ependymal giant 
cell astrocytoma13. 
Although mTOR inhibitors reduce the rate of loss of FEV1 in those with progressive disease, some of those 
treated continue to decline and it is not clear how to manage these individuals14 15. Further, mTOR 
inhibition is associated with oral mucositis, nausea, diarrhoea, oedema, acne, hyperlipidaemia, proteinuria, 
pneumonitis and a theoretical risk of future malignancy14. As many women with LAM develop progressive 
disease in their thirties, the potential cumulative exposure to mTOR inhibitors over decades means the risk 
of adverse effects is significant. Although data from clinical trials and selected populations have reported 
clinical response and side effects7 16 how these are related to drug levels has not been examined. As LAM is 
an orphan disease with no surrogate markers of disease activity, performing conventional randomised 
studies to understand different treatment regimens requires international collaborations over many years 
at potentially prohibitive cost. To address how to best preserve lung function, limit side effects from mTOR 
inhibition and inform future clinical trial design, we used a prospective national cohort study of women 
with LAM treated with rapamycin for progressive lung disease over a period of one to six years study to 
examine the relationship between lung function response, side effect profile and clinical features.  
 Methods 
The study was conducted at the National Centre for Lymphangioleiomyomatosis at Nottingham University 
Hospitals NHS Trust between 2011 and 2017. The Centre is funded by highly specialised commissioning for 
NHS England to provide a comprehensive clinical service for women with LAM in the UK. Women receiving 
care at the LAM Centre are invited to participate in an observational cohort study. The study was approved 
by the East Midlands Research Ethics Committee (13/EM/0264) and all participants gave written informed 
consent.  
The diagnosis of LAM was made according to American Thoracic Society criteria12. Clinical history, lung 
function, imaging and blood samples were collected at recruitment. Duration of disease was calculated as 
the interval between the first symptom attributable to LAM (e.g. first pneumothorax or onset of dyspnoea) 
and the start of treatment with rapamycin. 
All subjects had progressive lung disease. The decision to start rapamycin was made on clinical grounds 
alone. Subjects were treated according to a standard clinical protocol: individuals had baseline full blood 
count, urea and electrolytes, liver function tests, lipid profile, urine protein / creatinine ratio (PCR) and a 
pregnancy test. All were counselled on the indication for treatment, need for monitoring, potential adverse 
effects and drug interactions. Advice was given around intercurrent illness, surgery, pregnancy and 
supported with written information. All were given contact details of the Centre nurse specialist for queries 
and advice. 
Rapamycin, generally one or two mg orally once daily, was prescribed and a trough level measured 10 – 14 
days later. One month later, subjects returned for a clinical assessment of side effects, a trough rapamycin 
level, full blood count, urea and electrolytes, liver function tests, lipid profile, urine protein / creatinine 
ratio and the dose adjusted on the basis of serum level or side effects if required. After three months, these 
tests were repeated and FEV1 and DLCO measured. This assessment was repeated at six months of 
treatment and every six months thereafter. Subjects saw both a consultant physician (SJ) and nurse 
specialist (SF) at each visit and side effects were recorded. 
Lung function was measured according to ATS/ERS standards17 with predicted values calculated using 
regression equations from Quanjer at al.18. Change in FEV1 over time (ΔFEV1) was calculated as the 
regression slope of all FEV1 measurements taken either before rapamycin or during treatment using 
Microsoft Excel as described19 15. As shorter periods of observation and fewer individual measurements are 
associated with variation away from the group mean for ΔFEV1 in those with LAM19, ΔFEV1 was only 
reported for periods of observation of 1 year or greater. Serum vascular endothelial growth factor-D (VEGF-
D) was measured using a human quantikine VEGF-D ELISA (R & D Systems, UK). Serum cholesterol, urea and 
electrolytes, full blood count, liver function and urine PCR were measured in the clinical service laboratory 
at Nottingham University NHS Trust. 
Data were analysed in GraphPad Prism version 7.03 (GraphPad Software, La Jolla, CA USA), MS Excel and 
SPSS version 24 (IBM Corporation, Armonk, NY USA). Data were tested for normality using the D’Agostino-
Pearson test. Paired ΔFEV1 values before and after therapy were compared by paired t-test, comparison of 
cholesterol and PCR before and after treatment by paired t-test for the individual subjects, non-parametric 
data by Fischer’s exact and Chi square tests and association of rapamycin level with side effects and 
laboratory markers by Pearson correlation. T-tests were reported uncorrected unless stated. Comparison of 
pre-treatment disease duration and lung function, drug level and phenotype characteristics with ΔFEV1 was 
performed for the quartiles with the best and poorest response to rapamycin by unpaired t-tests and for 
the group as a whole by multivariate analysis. P values of <0.05 were considered significant. 
 
Results 
Study cohort 
Forty-seven women with definite LAM defined by ATS criteria and progressive lung disease who had been 
treated with rapamycin for longer than one year were included in the study. The mean age at the start of 
treatment was 43.6 (standard deviation 8.2) years and the mean duration of treatment 35.8 (SD 18) 
months equating to 143 patient/years of treatment observation.  Mean pre-treatment FEV1 was 52% (19) 
and DLCO 42% (12) of the predicted values. Nine (19%) had TSC, 18 (38%) had a history of pneumothorax, 
angiomyolipoma was present in nine (19%) and lymphatic complications, defined as chylous collections or 
lymphatic masses visible on CT scanning, were also present in nine (19%) individuals. 
 
Effect of rapamycin on ΔFEV1 
Twenty-one of the 47 individuals also had more than one year of observation of lung function prior to 
treatment with rapamycin. The remaining 26 had been treated elsewhere or required treatment at 
diagnosis and pre-treatment data were not available. There was no significant difference in age, baseline 
lung function or response lung function response to rapamycin within those with and without pre-
treatment data. Within these 21, the mean duration of observation was 38 (SD 22) and 36 (SD 20) months 
pre and post treatment respectively. Mean pre-treatment ΔFEV1 was -150 ml/yr (95% CI -220 to -79) and 
during treatment was +35 ml/yr (95% CI +9 to +61. p<0.0001). Furthermore, loss of FEV1 improved during 
rapamycin treatment in all individuals (Figure 1a).  
For all 47 subjects, mean treatment ΔFEV1 was +11 (SD 75) ml/yr although between individuals ΔFEV1 varied 
from +254 to -148 ml/yr. To understand the characteristics associated with differing responses to 
rapamycin, subjects were analysed in two ways. First, subjects were divided into quartiles according to their 
treatment ΔFEV1 (Figure 1b). The 25% of those with the highest positive ΔFEV1 when treated with 
rapamycin (quartile 1) had significantly higher pre-treatment FEV1 and shorter disease duration than the 
25% of those with the lowest negative ΔFEV1 (quartile 4). There was no significant association with serum 
rapamycin level (Figure 1c), the presence of angiomyolipoma, pneumothorax or lymphatic complications 
(Table 1). Those with the highest or lowest values of ΔFEV1 tended to have periods of observation of less 
than three years (Figure 1d). Next, the relationship between ΔFEV1 and pre-treatment disease duration, 
pre-treatment FEV1 and DLCO were subjected to multivariate analysis for all subjects. In initial univariate 
analyses, disease duration (unadjusted p=0.02), baseline FEV1 (unadjusted p=0.006) were associated with 
treatment response, although baseline DLCO was not (unadjusted p=0.33). Neither disease duration nor 
baseline FEV1 remained significant in a subsequent multivariate analysis.  
 
To determine if the lack of association between serum rapamycin levels and treatment response was due 
to maintaining higher serum drug levels in those with more severe disease, we examined the association 
between rapamycin level and baseline lung function. There was a slight negative correlation between 
rapamycin level over one year and baseline FEV1 (r=-0.37 (95% confidence interval -0.62 to -0.048), 
p=0.026) but not DLCO (r=-0.28 (95% confidence interval -0.56 to 0.054), p=0.099).  
 
Side effects of rapamycin 
Due to follow up schedules, intercurrent illness and travel issues to the LAM centre, eleven subjects had 
some missing values for rapamycin levels or side effects and these subjects were excluded from the side 
effect profile analysis. Most individuals experienced side effects which required a dose reduction in 25% of 
cases although all continued with treatment. The most common side effects were apthous ulcers, nausea, 
acne, oedema and menstrual irregularities (Table 2). Within the first month of therapy apthous ulcers, 
nausea and diarrhoea were most common. These fell from 59, 32 and 24% after one month to 15, 7 and 2% 
respectively after one year of therapy (Figure 2a). The incidence of acne, oedema and menstrual 
irregularities tended to increase over the first year of therapy from 7, 5 and 0% respectively at one month 
to 17, 12 and 7% of individuals respectively at 12 months. By the end of the observation period (mean 
treatment duration of 35.8 months), the prevalence of all side effects was 5% or less in all those treated. 
Pneumonitis was not observed at any time. 
 Relationship between side effects and rapamycin level 
We next examined the association between serum rapamycin level and the six most common side effects 
over the first month and first 12 months of treatment. After one month, 40% of those with a rapamycin 
level <3 pg/ml developed apthous ulcers but none of the other six common side effects. During the first 
month of treatment, apthous ulcers and diarrhoea were associated with increasing rapamycin levels (Figure 
2b). An increasing incidence of apthous ulcers and diarrhoea was also associated with higher mean serum 
rapamycin levels over one year, as were nausea, acne and menstrual irregularities (Figure 2c). Whilst the 
prevalence of individual side effects for differing rapamycin levels did not allow statistical analysis the total 
occurrence of the six major side effects was positively correlated with mean rapamycin level over one year 
(r=0.39, p=0.02). 
 
Effect of rapamycin on laboratory values 
Treatment with rapamycin was associated with a significant elevation of serum cholesterol within the first 
month of treatment from a baseline of 5.1 mmol/l (95% CI 4.8-5.4) to 5.6 (95% CI 5.2-6.0) which was 
sustained for the whole duration of treatment (Figure 3a). Urinary PCR was variable between individuals 
although there was a trend toward an increase PCR over the first year of treatment this returned to pre-
treatment values over the course of treatment (mean duration 35 months. Figure 3a). There were no 
significant changes in haemoglobin, renal or liver function over the treatment period (data not shown). 
Although those with higher plasma rapamycin levels tended to have the larger elevations of serum 
cholesterol, the serum level of rapamycin over 12 months of treatment was not significantly related to the 
increase in either cholesterol or urine PCR (Figure 3b). 
 
Discussion 
We have examined the lung function response to rapamycin and related side effects in a prospective 
national cohort of women with progressive lung disease due to LAM. Overall, rapamycin was associated 
with reduced disease progression but a significant minority continued to lose lung function at an 
accelerated rate. Whilst side effects were common, particularly at higher doses of rapamycin, they did not 
require cessation of therapy and remained at tolerable levels over several years. Likewise, elevations in 
serum cholesterol and proteinuria were small and manageable.  
In all cases, treatment with rapamycin was associated with improvements in ΔFEV1. In this study the mean 
ΔFEV1, observed for almost three years of treatment was +11 ml/yr and similar to that observed over 
shorter periods and in other cohorts5 14. What is striking is the variability in post treatment ΔFEV1 which 
although observed in other studies, has not been previously addressed. Those with the most favourable 
values of ΔFEV1 tended to have had LAM for less time and had better lung function, particularly FEV1, at the 
start of treatment, importantly this favourable lung function response was not simply accounted for by 
higher rapamycin levels in this group. It is possible that those with the least response to rapamycin have 
disease that is less dependent on mTOR dysregulation as suggested by the finding that signalling pathways 
other than mTOR contribute to tumourigesis in LAM cells20. In addition, VEGF-D is synthesised by LAM cells 
and is a transcriptional target of mTOR: the finding that higher levels of serum VEGF-D are associated with a 
better response to rapamycin is potentially consistent with differing levels of mTOR dysregulation and 
influence on the disease phenotype between individuals21. Conversely, resistance to rapamycin may be 
acquired over time as occurs in breast cancer cells in vitro22: with potential mechanisms including cellular 
efflux of rapamycin by ATP binding cassette transporters, mutations in rapamycin binding proteins, 
including FKBP, or loss of function or feedback in pathways such as Akt and retinoblastoma protein 
mediating some rapamycin dependent growth effects23 24. It is also possible that in more advanced disease, 
LAM related tissue remodelling itself, including recruitment of wild type cells can support LAM nodule 
growth and lung destruction, independent of mTOR signalling25. LAM is variable both in severity and its 
clinical manifestations and it is conceivable that specific LAM phenotypes, or groups of clinical features may 
be associated with favourable or unfavourable responses to rapamycin. The finding that those with the 
most and least favourable responses had different pre-treatment characteristics, but these characteristics 
were not significant in across the group as a whole, suggests those with good or poor responses to mTOR 
inhibition have different phenotypes or drug sensitivity rather than all patients being part of a continuous 
spectrum of rapamycin responsiveness, although larger prospective studies will be required to address this 
point definitively. Previous reports have suggested that those with chylous complications respond well to 
rapamycin11 and although in our study, those with positive values of ΔFEV1 had more lymphatic disease 
than those with negative ΔFEV1 values, this was not significantly different overall. It is possible the benefit 
obtained from rapamycin in lymphatic remodelling leading to reductions in lymphatic masses and chylous 
collections does not translate into longer term effects on lung parenchymal damage. However our study 
was not powered to definitively assess the association of individual or groups of clinical features and 
treatment response.  
We were interested to observe that there was no association between ΔFEV1 and serum rapamycin level. 
Although there was a weak association between serum rapamycin level and lower FEV1 at the start of 
therapy, we cannot completely exclude the possibility that the lack of a dose response relationship was due 
to this, although the level of difference is unlikely to have influenced the findings significantly. Our findings 
would be consistent with the idea that serum levels greater than 2 pg/ml are sufficient to treat progressive 
lung disease in most women with LAM. Whilst most clinical trials of rapamycin showing benefits on lung 
function and angiomyolipoma have titrated serum levels to 5 - 10 pg/ml, a retrospective study has 
suggested that lower serum rapamycin levels may be equally effective26. Our study, examining the group as 
a whole, was unable to assess if there was a dose response relationship between rapamycin level and 
ΔFEV1 for individual subjects, however, this study would require very long periods of observation and has 
not yet been performed. 
 Side effects were common and tended to occur either at the start of treatment and reduce over time 
(mouth ulcers, nausea and diarrhoea) or some weeks into treatment and persist (acne, oedema, menstrual 
disturbance). In excess of one year of treatment, individual side effects occurred in less than five percent of 
individuals overall. Unlike lung function response, there was a relationship between side effects and serum 
rapamycin levels with mean serum level positively associated with the six most common side effects over 
one year with nausea and diarrhoea particularly increasing at higher serum levels. Changes in laboratory 
indices mainly comprised a persistent elevation in serum cholesterol and transient proteinuria but in no 
individuals resulted in the need to stop therapy. There was no clear correlation between rapamycin level 
and elevation in either urinary protein or serum cholesterol. 
Our study was a real world observational cohort of those receiving rapamycin for progressive lung disease. 
As the Centre provides care for over two thirds of the UK population with a range of ages, clinical 
phenotypes and severity the study benefitted from being an unselected group representative of the disease 
as a whole15. Subjects were treated according to a standard protocol and seen at all visits by the same 
clinical team and had lung function measured at the same centre. However, various limitations are inherent 
real-world cohorts, side effect reporting relied on patient recall and treatment duration was not the same 
for all participants. As a consequence, extremes of ΔFEV1 where values exceeded 100 ml/yr in either 
direction, tended to be those with a duration of observation of less than three years suggesting some of 
this variability may be attributed to shorter term variation or regression to the mean19. However even in 
those treated for longer periods there was still significant variability in response. As rapamycin has become 
the standard of care from those with progressive lung disease it is no longer possible to study untreated 
control subjects matched for disease severity. However these subjects had similar overall levels of base line 
lung function, lung function response and side effects seen in other studies including the MILES trial, a one 
year randomised placebo controlled trial of rapamycin5 14. Although serum rapamycin level and baseline 
lung function were not examined in the MILES trial, MILES has been the only other study to examine 
variability in response to rapamycin where a poorer response over one year was associated with low 
baseline serum VEGF-D values, perhaps consistent with less mTOR dependent disease5 21. 
Our findings have clinical implications and suggest that lower serum rapamycin levels are associated with 
fewer side effects but no reduction in efficacy with potential benefits in reduced long term toxicity and 
costs. The observation that better responses were associated with earlier disease is consistent with the 
idea that early intervention with low dose rapamycin may be the best way to preserve lung function. The 
decision on when to offer treatment with rapamycin to balance preservation of lung function against 
cumulative side effects, and indeed the risk of unnecessary treatment of some individuals, is a critical issue 
for physicians and women with LAM. The recent ATS/JRS statement recommends the introduction of 
treatment for those with FEV1 or DLCO <70% of the predicted value12. It is currently not known how best to 
identify those with active disease earlier in their natural history. Those with active disease may include 
those with falling FEV1 whilst still in the normal range, those with normal spirometry but impaired DLCO or 
exertional hypoxaemia. In addition, higher levels of VEGF-D and younger age at presentation are more 
likely to indicate active disease and benefit from early treatment. The use of lower doses of rapamycin than 
previously studied with the aim of preserving lung function in early disease is to be tested in a randomised 
clinical trial (ClinicalTrials.gov Identifier: NCT03150914). It is also important to recognise that some treated 
with rapamycin continue to lose lung function at an accelerated rate and a formal study of disease 
phenotypes associated with poor lung function response and a protocol considering adjunctive therapy to 
rapamycin would improve management of individuals with aggressive and less mTOR inhibitor responsive 
disease although would require international collaboration.
Table 1. Clinical characteristics of quartiles of ΔFEV1 response to rapamycin 
 
ΔFEV1 response quartile Q1 Q2 Q3 Q4 Q1 vs Q4 
(p=) n 11 12 12 12 
Rapamycin treated ΔFEV1 
range (ml/yr) 254 to 56 50 to 0 -1 to -30 -31 to -148 - 
mean (ml/yr) 111 (58) 28 (15) -17 (11) -71 (41) <0.0001 
duration of treatment (yrs) 2.4 (1.3) 3.4 (1.6) 2.8 (1.1) 2.4 (2.1) 0.09 
Clinical characteristics at start of treatment 
pre-treatment ΔFEV1 (ml/yr)† -186 (238) -100 (69) -152 (77) -53 (202) 0.20 
age (yrs) 41 (9) 45 (11) 44 (8) 45 (6) 0.13 
disease duration (yrs) 6.1 (5.3) 13.0 (10.2) 8.2 (5.0) 11.3 (5.9) 0.02 
FEV1 (% predicted) 67 (23) 42 (10) 52 (17) 48 (20) 0.02 
DLCO (% predicted) 46 (11) 40 (10) 45 (14) 40 (15) 0.13 
Disease features present 
angiomyolipoma 6 5 6 3 NS 
lymphatic disease 3 3 1 2 NS 
TSC 3 2 2 2 NS 
ever had pneumothorax 5 4 6 3 NS 
Post treatment laboratory values 
trough rapamycin level (ng/ml)*  4.2 (1.2) 5.2 (1.2) 5.6 (1.7) 5.2 (1.5) 0.07 
urine protein/creatinine ratio** 8 (5-366) 9 (6-43) 11 (5-79) 8 (6-15) 0.84 
† for 21 subjects only. * mean value over 12 months (p for t-test). ** median (range) value after 12 months 
(p for Mann-Whitney test). NS for non-parametric data analysed by Chi square and Fischer’s exact test. 
  
Table 2. Side effects experienced whilst taking rapamycin according to duration of treatment and 
categorised by the Common Terminology Criteria for Adverse Events. 
 % affected 
Treatment duration (months) 1  6  12  latest ever 
Common Terminology Criteria for Adverse Events Category 
Gastrointestinal 
  Oral mucositis 
  Diarrhoea 
  Nausea 
  Abdominal  pain 
  Indigestion 
  Bloating 
  Reflux symptoms 
 
58 
32 
24 
6 
6 
0 
0 
 
35 
12 
3 
0 
0 
3 
0 
 
24 
10 
5 
0 
0 
5 
0 
 
13 
0 
0 
0 
0 
6 
5 
 
65 
41 
24 
6 
6 
9 
5 
Dermatologic 
  Acne 
  Rash 
  Dry skin 
 
6 
3 
6 
 
17 
10 
0 
 
18 
0 
0 
 
0 
0 
0 
 
41 
12 
6 
Soft tissues 
  Peripheral oedema 
 
5 
 
7 
 
0 
 
0 
 
9 
Sexual or reproductive function 
  Menstrual cycle disturbances 
 
0 
 
7 
 
5 
 
0 
 
15 
Constitutional symptoms 
  Fatigue 
 
3 
 
7 
 
0 
 
5 
 
9 
Infection 
  Upper respiratory / bronchitis 
  Tonsillitis 
  Pneumonia 
  Urinary tract infection 
  Skin infection 
 
12 
3 
0 
0 
3 
 
24 
7 
3 
7 
7 
 
10 
0 
0 
0 
0 
 
13 
0 
5 
0 
0 
 
35 
6 
5 
6 
9 
Musculoskeletal 
  Arthralgia or myalgia 
 
3 
 
3 
 
5 
 
0 
 
6 
 
Figure legends. 
Figure 1. Change in FEV1 in response to rapamycin. (a) Loss of FEV1 (ΔFEV1) in individuals prior to and 
during treatment with rapamycin. ΔFEV1 improved in all of those treated and was significant in the group as 
a whole. (b) Variation in ΔFEV1 between 47 individuals treated with rapamycin. (c) Lung function response 
to rapamycin (ΔFEV1) is not related to mean serum rapamycin level over one year. (d) Relationship between 
ΔFEV1 and duration of rapamycin treatment. Outlying values of ΔFEV1 tend to be associated with shorter 
durations of observation.  
Figure 2. Side effects of rapamycin treatment. (a) Relationship between side effects and treatment 
duration. Colours of markers and side effects are consistent in subsequent figures. (b) Side effects 
according to rapamycin level after one month of therapy. (c) Side effects according to rapamycin level after 
one year.  
Figure 3. Effect of rapamycin on serum cholesterol and urine protein. (a) Mean and standard error of 
plasma cholesterol and urine protein / creatinine ratio (PCR) during treatment. (b) Association of serum 
rapamycin level with serum cholesterol and urine PCR after one year of therapy. 
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